• Chris Bunka, Lexaria’s CEO, has reiterated the company’s commitment to creating value for its shareholders with the licensed use of its patented DehydraTECH(TM) technology
• Mr. Bunka has noted that Lexaria is already in discussions with interested parties in Europe and North America, a move that presents a critical fiscal opportunity for the company
• He has emphasized how profitable new licensing agreements could be for the company, presenting additional avenues for Lexaria to generate revenue and create value for its shareholders
• As the company continues to make a transition toward a more commercial focus in 2023, Bunka notes that licensing will play an integral part

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has, since its inception, stayed committed to creating shareholder value and exploring different avenues for growth. This outlook has informed the company’s ambitious clinical studies, starting with the HYPER-H21-4 clinical study demonstrating a novel mechanism of action of its patented DehydraTECH(TM)-processed cannabidiol (“CBD”) capsule formulation for the reduction of blood pressure. It has also shaped other studies, including, but not limited to, diabetes, nicotine replacement, antivirals, and human epilepsy.

In the most recent annual letter to all stakeholders, dated January 2023, Chris Bunka, Lexaria’s CEO, reiterated the company’s commitment to creating value for its shareholders. Of note was his mention of the licensed use of its DehydraTECH technology, both for consumer sectors and the pharmaceutical industry. In addition, Bunka noted that the company was already in discussions with interested parties in Europe and North America, which presents a key fiscal opportunity for the company as time progresses (https://cnw.fm/eIiuX).

In the letter, Mr. Bunka broke down the financial upside to this move by Lexaria, citing how profitable it could be for the company in the immediate and distant future.

“For companies with sales of $10 billion or $30 billion per year, this makes sense. And given that Lexaria’s business model is to out-license our technology in exchange for royalties, you can see very quickly how every single percentage point of royalty on each $1 billion in revenue, amounts to $10,000,000 per year in highly profitable revenue to Lexaria,” Bunka noted.

“A 3% royalty rate on $4 billion would be $120,000,000 in revenue; or an 8% royalty on $2 billion would be $160,000,000 in revenue,” he added.

Lexaria’s licensing opportunities are constantly evolving. So far, the company’s DehydraTECH technology can be used to improve existing products or even create new products. In addition, the technology has proven suitable for a broad range of consumer products such as oral suspensions, topicals, nutraceuticals, registered drugs, capsules, pills, and tablets, among others.

As a technology designed to be effective in delivering fat-soluble molecules through the human gastrointestinal system, DehydraTECH has demonstrated an affinity for transdermal applications, which have shown effectiveness in crossing the blood-brain barrier once within blood plasma. This, in addition to other benefits such as doing away with the need for sugar-filled edibles, more efficiency, and the overall lowering of drug costs, has drawn the attention of parties interested in this technology, ultimately opening up Lexaria’s licensing opportunities.

As an avenue for generating revenue for the company, Bunka is optimistic that the licensing fees will significantly complement its royalty revenue generation while providing it with the much-needed capital to keep advancing its clinical studies and improving its technology.

“Lexaria expects licensing fees to significantly complement its royalty revenue generation and also allow it to realize commercial revenue generation well in advance of when revenues start to flow from royalties upon actual product sales under these licensing transactions,” he noted.

As Lexaria continues to transition towards a more commercial focus, licensing will play an integral part. It will be a fundamental aspect of building a successful and profitable future for the company while also forming a solid foundation for more ambitious future clinical studies.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

• DehydraTECH(TM)-enabled drugs and product formats improve the speed of onset, increase bioavailability, increase brain absorption, enhance drug potency, reduce drug administration costs, and mask unwanted tastes, shown effective with a growing number of medical applications
• Current DehydraTECH studies (animal and human) include hypertension, dementia, oral nicotine, epilepsy, and diabetes
• Most recently, Lexaria’s DehydraTECH-CBD studies for hypertension have produced positive results, and the company is seeking IND status with the FDA

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has developed a disruptive drug delivery technology with multiple opportunities for success in cannabinoids, oral nicotine and other active pharmaceutical ingredients (“APIs”). Lexaria’s patented DehydraTECH(TM) technology is a formulation and dehydration processing procedure that changes how the body detects and absorbs drugs. The company currently has 28 granted patents, with many more pending patents in countries worldwide.

Lexaria specifically designed DehydraTECH for formulating and delivering topical or oral lipophilic (fat-soluble) drugs and APIs to increase effectiveness and improve how they enter the bloodstream. The major benefits of a DehydraTECH-enabled drug or consumer product include the following:

• Faster delivery time – the effects of the product are felt by the subject in minutes
• Increased bioavailability – the technology is more effective at delivering a drug or product into the bloodstream
• Increased brain absorption –testing suggests significant improvement in the quantity of the drug or product delivered across the blood-brain barrier
• Improved drug potency – more of the drug or product is made available in the body, requiring lower dosages for the desired outcome
• Reduced drug administration costs – lower dosages mean lower overall drug costs
• Improved taste – the technology eliminates the necessity for sweeteners to eliminate or reduce unwanted taste

One of Lexaria’s studies is cannabidiol (“CBD”) for hypertension, which has produced positive results for the company to seek Investigational New Drug (“IND”) status with the United States Food and Drug Administration (“FDA”). The company has completed a pre-IND meeting and intends to file for IND status in 2023. Lexaria’s first and subsequent DehydraTECH-CBD human studies have shown superior human blood absorption levels and demonstrated a potential novel mechanism of action in reducing blood pressure. More information on Lexaria’s current studies can be found on the company’s fact sheet (https://ir.lexariabioscience.com/presentations).

The global non-prescription CBD market was valued at $4.9 billion in 2021 and is expected to reach $47.22 billion in 2028, growing at a CAGR of 21.3% (https://cnw.fm/Iqpis). There has also been increased product acceptance and use due to FDA approval of one type of CBD. CBD is being studied in a variety of medical applications worldwide, including anxiety and depression treatment, stress reduction, diabetes prevention, pain relief, cancer symptom relief, and inflammation relief. Lexaria is currently exploring DehydraTECH-CBD-enabled formulations for hypertension, epilepsy, diabetes and dementia indications.

Since 2016, Lexaria’s DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption, reduce onset time from hours to just minutes, and mask unwanted tastes. The company intends to further evaluate the technology for other oral and topical use potential in cannabinoids, oral nicotine and other APIs.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

• Lexaria Bioscience, a global innovator in drug delivery platforms, has developed and patented the DehydraTECH(TM) drug delivery platform technology
• The company has undertaken multiple studies as part of its extensive R&D program involving DehydraTECH, which continues to yield positive results
• This R&D program is focused on the development of product candidates across four main segments, which represent the platform’s potential commercial applications
• These segments include the development of DehydraTECH-processed cannabidiol (“CBD”) for hypertension, epilepsy, diabetes and dementia; DehydraTECH-processed oral nicotine; other pharmaceutical areas exploring a wide range of DehydraTECH-processed active molecules; and hemp-derived CBD applications for consumer packaged goods (“CPG”)
• Currently, Lexaria is prioritizing research on DehydraTECH-CBD as a potential treatment for hypertension

Recent advancements in drug delivery techniques have improved, among others, the efficiency and safety of therapeutic treatments and active pharmaceutical ingredients (“APIs”). In fact, analyzing these improvements through the findings obtained by Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, demonstrates the progress is remarkable. Headquartered in Kelowna, British Columbia, the company developed and patented the DehydraTECH(TM) drug delivery platform technology, which is essentially an additional step easily incorporated into the formulation and manufacturing process of existing or new orally ingestible and topical lipophilic (fat-soluble) products.

“This step involves mixing the active ingredient as a delivery ‘payload’ together with certain fatty acids, infusing the mixture into a substrate material, and then using controlled dehydration synthesis processing to associate the payload and fatty acids together at a molecular level, before integrating the newly combined molecules into end-product production across a range of dosage form factors,” explains Lexaria’s website (https://cnw.fm/qSJcy).

According to the company’s extensive studies, its patented DehydraTECH(TM) technology has been shown to enhance the bioavailability (the proportion of the ingested drug that enters the bloodstream) of APIs and increase brain absorption by up to 17x, with the effects felt in minutes (https://cnw.fm/XmuuJ). Other proven benefits include the fact that APIs processed using the technology platform are rendered largely flavorless and odorless, meaning manufacturers no longer have to add sweeteners or chemical masking agents. As a result and using DehydraTECH, they can create low-sugar products with fewer calories while avoiding the use of excessive artificial sweeteners. This is particularly positive, considering that recent studies suggest that consumption of excessive artificial sweeteners predisposes consumers to elevated blood sugar levels and raises their risk of developing stroke or heart disease (https://cnw.fm/WDsja).

The above DehydraTECH-related findings are part of Lexaria’s extensive repository of positive results generated by its ongoing research and development (“R&D”) program. This program focuses on the development of product candidates across four main segments, which are intended to eventually serve as the platform’s commercialization avenues. These include the development of DehydraTECH-processed cannabidiol (“CBD”) for hypertension, epilepsy, diabetes and dementia; DehydraTECH-processed nicotine delivered via non-combustive methods; other pharmaceutical areas exploring a wide range of DehydraTECH-processed active molecules, including antiviral drugs, hormone treatment, phosphodiesterase inhibitors, and more; and hemp-derived CBD applications for consumer packaged goods (“CPG”).

To date, Lexaria has undertaken multiple studies aimed at improving the commercialization prospects of the platform. “Our applied R&D programs completed since [our up-list to the Nasdaq exchange and capital raise in 2021] have yielded almost entirely positive results – a crucial accomplishment as we prepared to use those results to reinforce our outreach strategy to potential corporate partners,” CEO Chris Bunka stated in his annual letter to shareholders published January 2023 (https://cnw.fm/RHovC).

Bunka added that the applied R&D “is paying off in spades” because the company is currently engaged in active discussions with several multi-billion dollar companies around the world for the potential use of its DehydraTECH technology in their commercial products pursuits. And while the company cannot disclose the identities of these potential partners prior to the signing of definitive agreements, stakeholders and shareholders can, in the meantime, focus on the positive results of its R&D program, which are bellwethers of potential success.

For instance, in a recent diabetes animal model study, DIAB-A22-1, Lexaria reported at least three positive outcomes, including weight loss in obese diabetic-conditioned animals, a statistically significant improvement in locomotor activity, statistically significant reductions in triglyceride levels (high levels in the blood can suggest the onset of diabetes), and increased levels of HDL cholesterol, the ‘good’ kind of cholesterol (https://cnw.fm/mXYH8).

These findings are the latest in a series of studies evaluating DehydraTECH-CBD as a potential treatment for a number of conditions, including diabetes, dementia, epilepsy, and hypertension, with the latter being the company’s primary and most advanced R&D program in this pipeline. To date, Lexaria has undertaken five human clinical studies evaluating DehydraTECH-CBD for hypertension. In 2023, the company expects to launch an FDA-registered Investigational New Drug (“IND”) program to formally investigate DehydraTECH-CBD, at the Phase 1b stage. And given the success witnessed in the five previous clinical trials, Lexaria believes it has effectively de-risked the upcoming FDA-registered program.

This program, Bunka wrote, is expected to dominate the company’s second half of 2023 and beyond, and “will be a major step in our maturation as a pharmaceutical company and will be our primary research focus once it begins. If it is successful, it should contribute to an increase in our corporate value and an increase in the likelihood of our reaching one or more commercial agreements within the pharmaceutical industry.”

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cbdwire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.cbdwire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, is positioned for opportunity with its patented DehydraTECH(TM) technology and its wide-reaching potential. “Lexaria’s DehydraTECH is designed to formulate and deliver lipophilic (fat-soluble) drugs and active pharmaceutical ingredients (‘APIs’). DehydraTECH increases the effectiveness of and improves the way APIs enter the bloodstream. The benefits of consuming a DehydraTECH-enabled drug or product include: speed up in delivery time; increased bioavailability; increased brain absorption; improved drug potency; and reduction in drug administration costs. Animal studies of DehydraTECH have demonstrated the ability to elevate the quantity of the drug delivered across the blood-brain barrier by as much as 1,900%,” a recent article reads. “Lexaria’s technology is best thought of as a foundation that providers of drugs and consumer supplements can utilize to improve the effectiveness of their existing or planned new offerings. DehydraTECH is suitable for use with a wide range of product formats, including pharmaceuticals, nutraceuticals, and over-the-counter capsules, pills, tablets, or oral suspensions.”

To view the full article, visit https://cnw.fm/3oeyM

About Lexaria Bioscience Corp.

Lexaria’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream through oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 28 patents granted and many patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

• Chris Bunka, Lexaria’s CEO, remains confident that 2023 will be Lexaria’s best year ever and has expressed his optimism that the company will continue to build its client base and increase its cash flows as the year progresses
• In his 2023 letter to stakeholders, the CEO expressed his satisfaction given that the company had delivered on a statement that he made the previous year, lauding his team for meeting objectives that Lexaria had set out to achieve in the 2022 calendar year
• Through the help of his team, Bunka is committed to making Lexaria one of the top drug delivery performers in the biotech/pharmaceutical world, starting with the launch of its FDA-registered IND program to investigate its patented DehydraTECH(TM)-processed CBD for the potential treatment of hypertension

Back at the start of the 2022 calendar year, Chris Bunka, the CEO of Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, released his annual letter to all stakeholders. Of note was his emphasis on the company’s initiatives to have multiple choices in how it was funded, specifically trying to position Lexaria for non-dilutive injections of capital through strategic partners and other commercial relationships  (https://cnw.fm/icp9D).

In his 2023 letter, Bunka expressed his satisfaction and pleasure, given that the company delivered on the statement he made the previous year, pointing to his team for delivering objectives that Lexaria had set out to achieve in the 2022 calendar year.

Under the able leadership of John Docherty, Lexaria’s President and Director, as well as Gregory Downey, the Chief Financial Officer (“CFO”), the company has built on the progress made in 2022 to begin the transition toward a more commercial focus.

Lexaria was granted new patents in 2022, bringing its total to 28 granted patents worldwide across the United States, Canada, Mexico, Australia, Japan, India, and the European Union. The management expects to be awarded additional patents in the 2023 calendar year, even though it has already achieved considerable intellectual property protection through its existing patent portfolio.

Importantly, with its current positioning, Lexaria is seen as being able to fully operate through nearly all of 2023 without raising additional capital:

“In fact, we’ve done such a great job of preserving capital that we could survive through nearly all of 2023 without needing to raise additional capital, if we cut back a little on our R&D spending,” noted Bunka. “However, as we prefer to keep advancing our applied R&D at a rapid pace as we can, we are also continuing to pursue capital-strengthening possibilities that do not involve the issuance of any equity,” he added.

Going forward in 2023, Lexaria looks to launch its FDA-registered Investigational New Drug (“IND”) program to formally investigate its patented DehydraTECH(TM)-processed CBD for hypertension. The company also seeks commercial relationships this year, even as its R&D progresses. Bunka has also shared the possibility of additional investigations in 2023 related to DehydraTECH-CBD or other pharmaceutical areas of interest.

With the learnings from the previous year, Bunka is confident that 2023 will be Lexaria’s best year ever. With the company enjoying more successes than failures, its management hopes it will continue to build its client base and increase its cash flows as the year progresses.

“It is my goal for 2023 to make Lexaria Bioscience one of the top drug delivery performers in the biotech/pharmaceutical world as we continue to prove the validity of our technology, and really begin our efforts to deliver financial rewards to you, our owners,” noted Bunka.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator developing and commercializing its patented DehydraTECH(TM) drug delivery technology. Lexaria is continuing and/or initiating discussions with several larger companies in Europe and North America regarding the licensed use of its technology for both consumer and pharmaceutical sectors. “The materialization of such partnerships hinges on a number of must-haves. Firstly, there must be a tangible product that draws larger companies. Secondly, The decision of whether or not to invest, and the scale of any investment, is based on how well the technologies that form the core of a company have been protected. This is where patents come in. Moreover, the further a company can take its own research, the better the deal that will be offered in terms of upfront payments, milestone payments, and royalties,” reads a recent article that contains excerpts from a LabioTech writeup. “Lexaria ticks all these boxes. Its unique technology – DehydraTECH – is not only tangible but has also been shown to enhance the performance of several categories of fat-soluble active molecules and drugs across various oral and topical product formats. The technology is also protected by a robust portfolio of 28 patents granted worldwide as of February 2023… Lastly, and perhaps most importantly, Lexaria has substantially invested in research and development (‘R&D’), an aspect of its operations that is 100% within its control. According to CEO Chris Bunka, the company has designed its applied R&D to boost its commercial prospects, and this ‘is paying off in spades,’ as it has, among others, ‘yielded almost entirely positive results.’”

To view the full article, visit https://cnw.fm/dikY2

About Lexaria Bioscience Corp.

Lexaria’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream through oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 28 patents granted and many patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

• DehydraTECH(TM) is suitable for use with a wide range of product formats, including pharmaceuticals, nutraceuticals, and over-the-counter capsules, pills, tablets, topicals, oral suspensions and more
• The patented technology increases the speed of onset, bioavailability, brain absorption, and reduces drug administration costs
• Lexaria currently has multiple R&D programs – yielding successful results and further opportunities for additional study models

Lexaria Bioscience (NASDAQ: LEXX), a global innovator of drug delivery platforms, is increasing bioavailability and improving the way that active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery with its patented DehydraTECH(TM) technology. DehydraTECH is suitable for use with a wide range of product formats, including pharmaceuticals, nutraceuticals, and over-the-counter capsules, pills, tablets, topicals, oral suspensions and more.

Most recently, a company announcement indicates that a just-completed DIAB-A22-1 diabetes study has produced at least three positive outcomes, including weight loss in obese diabetic-conditioned animals and shown improved triglyceride and cholesterol levels (https://cnw.fm/ORSPL). The animals tested in the study showed these dramatic changes in as few as three days when dosed with DehydraTECH-processed cannabidiol (“CBD”), aligned with other study work pointing to CBD’s known anti-inflammatory and antioxidant properties. Lexaria is pleased that relatively low dosages of DehydraTECH-CBD seem to support real improvements in the lab animals’ day-to-day health and find encouragement in the positive findings from its first diabetes study.

In addition to DIAB-A22-1, some of Lexaria’s previous R&D programs include:

• HYPER-A21-1 – a rodent study demonstrating significant enhancement in CBD delivery using DehydraTECH with more CBD delivered into the bloodstream and brain tissue
• HYPER-A21-2 – a rodent study demonstrating the strongest CBD absorption results ever recorded
• HYPER-H21-1 – Human clinical study evidencing a rapid and sustained drop in blood pressure with excellent tolerability using DehydraTECH-CBD
• HYPER-H21-2 – Human clinical Hypoxic Pulmonary Vasoconstriction study with evidence of up to a 23% decrease in blood pressure confirming a reduction in arterial stiffness
• HYPER-H21-3 – Human clinical Pulmonary Hypertension Clinical Study intended to support Lexaria’s plan to seek FDA approvals
• HYPER-H21-4 – Human clinical study exhibiting exceptional safety and tolerability with statistically significant evidence of lowered blood pressure in patients and showed great absorption levels and potential novel mechanism of action in reducing blood pressure
• VIRAL-C21-3 – In vitro screening assay completed using primate cell line, VERO-E6, determining that remdesivir and ebastine processed with DehydraTECH were effective in inhibiting the COVID-19 virus
• VIRAL-A20-2 – A rodent study showing a three-fold increase in oral delivery of anti-viral drugs
• VIRAL-MC21-1 – research concluded that DehydraTECH processing and formulation technology does not create a covalently bonded new molecular entity or change in chemical structure
• VIRAL-A20-3 – A rodent study demonstrating significant enhancement in anti-viral drug delivery using DehydraTECH-enabled Colchicine with possible benefits of treating COVID-19 and mRNA vaccine side effects
• NIC-A21-1 – DehydraTECH-oral nicotine delivery peaked in the bloodstream 10x and 20x faster than controls, with peak levels achieved 10x higher than controls
• PDE5-A21-1 – DehydraTECH-sildenafil delivered 74% more drug at 4 minutes than the control
• EPIL-A21-1 – DehydraTECH-CBD has demonstrated performance enhancements compared to one of the world’s leading anti-seizure medications, Epidiolex(R)

Since 2014, Lexaria has been developing its patented DehydraTECH technology, which has yielded 28 granted patents and many more pending in countries worldwide. DehydraTECH’s evidenced benefits include the improved speed of onset, increased bioavailability, increased brain absorption, and reduced drug administration costs. As more research becomes available from Lexaria’s ongoing R&D programs, the company will provide updates.

Lexaria operates four subsidiary companies, focusing on different commercial opportunities in their respective industries:

• Lexaria Pharmaceutical Corp. investigates new products for hypertension, antiviral treatments, epilepsy, some pharmaceutical applications of nicotine and other drug classes
• Lexaria Nicotine LLC investigates oral non-combusted tobacco-derived nicotine product formats
• Lexaria Hemp Corp. pursues business-to-business opportunities with cannabinoids
• Lexaria Canpharm ULC operates a state-of-the-art Health Canada licensed laboratory capable of developing novel cannabinoid and other formulations for potential commercialization

Lexaria sub-licenses the company’s DehydraTECH technology for the delivery of fat-soluble active molecules and drugs.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently reported additional findings from its most comprehensive clinical study yet, HYPER-H21-4. “The findings showed that DehydraTECH-CBD resulted in a statistically significant reduction in average baseline serum catestatin concentrations of 13.50 ng/mL to just 9.65 ng/mL after five weeks of dosing, representing a 28.5% drop. In addition, mean arterial pressure significantly dropped by 4.26 ± 1.26 mm/Hg following the five weeks of DehydraTECH-CBD dosing. No statistically significant reductions in catestatin concentrations were identified in the placebo group,” a recent article reads. “Given the growing demand for alternative anti-hypertensive treatments and therapies, Lexaria recognizes an opportunity and seeks to fill it. These latest results from its ambitious HYPER-H21-4 study inch the company closer to achieving that goal, ultimately becoming a leader and tapping into a pharmaceutical market that is set to be valued at $34 billion by 2030. Lexaria’s management is optimistic that DehydraTECH-CBD and its effectiveness in modulating catestatin levels could become a significant value enhancer should it eventually enter the marketplace as an approved hypertension treatment.”

To view the full article, visit https://cnw.fm/G4QpC

About Lexaria Bioscience Corp.

Lexaria’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream through oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 28 patents granted and many patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

• Lexaria’s DIAB-A22-1 animal model study just concluded, highlighting three positive outcomes, including an improvement in general activity, significant reductions in body weight, and improved triglyceride and cholesterol levels
• The study was undertaken by a third-party testing laboratory in Canada involving 24 obese and eight lean rats for a total of 32 male Zucker rats
• The success of this DIAB-A22-1 study marks a significant milestone for Lexaria, even as it continues to explore its patented DehydraTECH(TM) technology application in various other areas, including nicotine replacement, epilepsy, hypertension, dementia and more
• With its unique product offering, a growing list of patents, and unique market positioning, Lexaria is becoming a key player in the drug delivery technology space

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced the completion of its DIAB-A22-1 animal model study, which explored the potential of the patented DehydraTECH(TM)-processed CBD to treat diabetes. Of note were three positive outcomes, including an improvement in general activity, reductions in body weight, and better triglyceride and cholesterol levels.

The study, undertaken by a leading, third-party testing laboratory in Canada, administered select Lexaria “DehydraTECH-CBD 2.0” formulations with doses of either 30 mg/Kg or 100 mg/Kg of body weight. It involved 24 obese and eight lean rats for a total of 32 male Zucker (“ZDF”) rats. As Lexaria’s first study in the diabetes animal model, the company is encouraged by the positive findings. Moreover, it is confident that the results indicate many prospective benefits worthy of further investigation together, possibly with other drugs that help to control glucose levels directly.

Lexaria set out to explore the therapeutic utility of DehydraTECH-CBD against diabetes in November 2022, on the heels of the success of its clinical studies on hypertension. The company’s management was optimistic that the results from the hypertension study would be replicated in the diabetes study, given that hypertension is twice as frequent in people with diabetes, and hypertensive patients are at greater risk of developing diabetes.

The success of this DIAB-A22-1 study marks a significant milestone for Lexaria, even as it continues to explore DehydraTECH’s application in various other areas, including nicotine replacement, epilepsy, hypertension, dementia and more. With DehydraTECH having proven to increase the effectiveness and the way active pharmaceutical ingredients enter the bloodstream, Lexaria is exploring its full potential for improving consumer products. Its efforts have seen the company awarded 28 patents, with more patents pending worldwide.

Diabetes is the 7th largest cause of death in the United States and accounts for an estimated value of $26.7 billion in the global diabetes devices market. Lexaria’s management is hopeful that its current efforts and studies will inch the company closer to taking advantage of this industry’s market potential. In 2021, the global diabetes drug market was estimated at $63.1 billion and is projected to hit $80.65 billion by 2027. With the company’s unique technology, a growing list of patents, and unique market positioning, Lexaria is set to capitalize on this growth and become a leader in the drug delivery technology space.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.